

## CURRICULUM VITAE

**Name:** STEVEN WILLIAM MAMUS, MD  
**Address:** 3830 Bee Ridge Road, Suite 301 – Sarasota, FL 34233  
**Cell Phone Number:** 941-780-5122  
**Business Phone Number:** 941-923-1872  
**Fax Number:** 941-923-3947  
**E-mail Address:** smamus@cancersarasota.com  
stevesarasota@gmail.com

### **EDUCATION:**

July 1983 – June 1986 Fellow, Hematology/Oncology, University of Minnesota Hospital,  
Minneapolis, Minnesota  
July 1981 – June 1983 Resident, Internal Medicine, Rush-Presbyterian St. Luke's Hospital  
Chicago, Illinois  
July 1980 – June 1981 Intern, Internal Medicine, Rush Presbyterian St. Luke's Hospital  
Chicago, Illinois  
Aug 1976 – June 1980 State University of New York at Syracuse  
MD  
Aug 1972 – June 1976 Harvard College  
BA

### **LICENSURES:**

Florida ME 48231  
Virginia 0101239600

### **Board Certification:**

9/1983 American Board of Internal Medicine – Internal Medicine  
11/1986 American Board of Internal Medicine – Hematology  
11/1987 American Board of Internal Medicine – Medical Oncology

**Professional Experience:**

11/27/2006 – Present	Cancer Center of Sarasota Sarasota, Florida Medical Director
2/2004 – Present	Cancer Centers of Florida ( US Oncology) Orlando, Florida Shareholder
7/1994 – 1/2004	M.D. Anderson Cancer Center – Orlando Orlando, Florida
7/1991 – 7/1994	Orlando Cancer Center Orlando Florida
7/1986- 7/1991	Hematology/Oncology Associates of Central Florida Orlando, Florida

**NOTE: practice 1986-2004 effectively all the same practice**

**Chronology of Employment & Appointments:**

1980-1983	Clinical Instructor, Rush Medical College, Chicago, Illinois
1980-1981	Intern, Internal Medicine, Rush-Presbyterian St. Luke's Hospital Chicago, Illinois
1981-1983	Resident, Internal Medicine, Rush-Presbyterian St. Luke's Hospital Chicago, Illinois
1983-1986	Fellow, Hematology/Oncology, University of Minnesota Hospital
1986-Present	Active Staff, Orlando Regional Medical Center, Main Campus, Orlando, Florida
1986-Present	Active Staff, ORMC, Sand Lake Campus, Orlando, Florida
1986-1991	Group Practice, Hematology/Oncology Associates of Central Florida Orlando, Florida
1986-1991	Courtesy Staff, Brookwood Community Hospital, Orlando, Florida
1986-1992	Courtesy Staff, Florida Hospital, Orlando, Florida
1991-1994	Orlando Cancer Center, Orlando, Florida
1994-2004	M.D. Anderson Cancer Center Orlando, Florida
2002-Present	National Speaker's Bureau, Astra-Zeneca Pharmaceuticals
2002-Present	Advisory Board Southeast Region Astra-Zeneca
2002	Executive Breast Cancer Advisory Council, Novartis Pharmaceuticals
2002-2005	Speaker's Bureau, Amgen
2002-2004	Advisory Board Lilly Pharmaceuticals
2002	Advisory Board Ortho Biotech
2002-2003	Advisory Board Roche Pharmaceuticals
2002-2003	Chief, Medical Oncology MD Anderson-Orlando

2002-2003	Section leader, melanoma, MD Anderson-Orlando
2002-2003	Section leader, soft tissue sarcoma, MD Anderson-Orlando
2002-2003	Section leader, breast carcinoma, MD Anderson-Orlando
2004-present	Active medical staff Florida Hospital System
2004-present	Active medical staff Health Central Hospital
2005-present	Active medical staff Osceola Regional Medical Center
2007-present	Professional Advisory Board member, The Wellness Community-SW Florida, Sarasota

**Hospitals**

Sarasota Memorial Hospital  
Doctors Hospital of Sarasota  
Lakewood Ranch Hospital  
Florida Hospital Healthcare System  
Florida Hospital South  
Florida Hospital East  
Florida Hospital North  
Florida Hospital Kissimmee  
South Lake Hospital  
Orlando Regional Medical Center  
Health Central Hospital

**Societies:**

1982 – Present	American Medical Association
1982 – 1983	American College of Emergency Physicians
1983 – 1986	American College of Physicians
1984 – 1986	American Federation for Clinical Research
1986 – Present	Florida Medical Association
1986 - Present	Orange County Medical Society
1986 - Present	American Society of Hematology
1987 – Present	Florida Society of Clinical Oncology
1988 – 1989	Bd. of Trustees, Leukemia Society of America, Orlando Chapter
1989 – Present	American Society of Clinical Oncology
2007	Sarasota County Medical Society

**Awards:**

1976	BA, cum laude, Harvard College
1984	Third Prize, Officer-Fellow Abstract Award, American Federation for Clinical Research, Midwestern Section
1985	First Prize, Midwest Trainee Award, American Federation for Clinical Research, Midwestern Section
1986	Research grant for study of Interferon Effects on Normal Hematopoiesis National Institutes of Health, Heart and Lung Institute (unrestricted individual grant for \$450,000.00-declined in favor of private practice).

1987	Attending Physician of the Year, Orlando Regional Medical Center, Department of Internal Medicine
1996	<b><i>The Best Doctors in America, Southeast Region</i></b> , 1996-1997 Edition
1997	<b><i>The Best Doctors in America, Southeast Region</i></b> , 1997-1998 Edition
1998	<b><i>The Best Doctors in America, Southeast Region</i></b> , 1998-1999 Edition
1999	<b><i>The Best Doctors in America, Southeast Region</i></b> , 1999-2000 Edition
2000	<b><i>The Best Doctors in America, Southeast Region</i></b> , 2000-2001 Edition
2001	<b><i>The Best Doctors in America, Southeast Region</i></b> , 2001-2002 Edition
2001	<b><i>American College of Physicians Excellence in Teaching Award</i></b>
2002	<b><i>The Best Doctors in America, Southeast Region</i></b> , 2002-2003 Edition
2003	<b><i>The Best Doctors in America, Southeast Region</i></b> , 2003-2004 Edition
2004	<b><i>The Best Doctors in America, Southeast Region</i></b> , 2004-2005 Edition
2005	<b><i>The Best Doctors in America, Southeast Region</i></b> , 2005-2006 Edition
2006	<b><i>The Best Doctors in America, Southeast Region</i></b> , 2006-2007 Edition
2007	<b><i>The Best Doctors in America, Southeast Region</i></b> , 2007-2008 Edition

**PUBLICATIONS/PRESENTATIONS:**

1. Mamus SW, Mladenovic J, Hordinsky MK, Dahl M and Kay NE. (1984) Cimetidine induced remission of mycosis fungoides. *Lancet*, II: 409.
2. Mamus SW, Beck-Schroeder SL and Zanjani ED. (1985) Suppression of normal human erythropoiesis by gamma interferon in vitro: role of monocytes and T lymphocytes. *Journal of Clinical Investigation* 75:1496-1503.
3. Mamus SW, Burton J, Groat JD, Schulte DA, Lobelle N and Zanjani ED. (1986) Ibuprofen associated pure white cell aplasia. *New England Journal of Medicine* 314:624-625.
4. Mamus SW, Oken MM and Zanjani ED. (1986) Cell-cell interactions erythropoiesis. *Transfusion Medicine* 227-244.
5. Mamus SW, Oken MM and Zanjani ED. (1986) Suppression of normal human erythropoiesis by human recombinant DNA-produced alpha<sub>2</sub> interferon in vitro. *Experimental Hematology* 14:1015-1022.
6. McGlave P, Mamus SW, Vilen B and DeWald G. (1987) Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. *Experimental Hematology* 15:331-335.
7. Moulis H and Mamus SW. Isolated trochlear nerve palsy in a patient with Waldenstrom macroglobulinemia: Complete recovery with combination therapy. *Neurology* 36:1399.

8. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, and Kantarjian HM. (2003) Phase II study of troxycitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. *Leukemia Research*.

**ABSTRACTS:**

1. Mamus, SW, Mladenovic J. and Kay NE. (1984) Cimetidine induced remission of mycosis fungoides. *Clinical Research* 32:418A.
2. Mamus, SW and Zanjani, ED. (1984) Interferon-induced suppression of erythroid colony formation by normal human bone marrow cells in vitro. *Experimental Hematology* 12:366.
3. Mamus, SW and Zanjani, ED. (1984) T lymphocytes activated with gamma interferon profoundly suppress human erythropoiesis in vitro. *Clinical Research* 32:789A.
4. Mamus, SW and Zanjani, ED. (1984) Gamma interferon mediated suppression of human erythroid colonies in vitro is mediated primarily via immunocompetent cells. Fourth International Conference of Hemoglobin Switching. Bethesda, Maryland.
5. Mamus, SW and Zanjani, ED. (1984) Gamma interferon induced suppression of erythroid colony formation by normal human bone marrow cells in vitro: Role of monocytes and T cells. Tenth Annual Frederick Stohlman Jr, MD Memorial Symposium. An International colloquium on stem cell physiology.
6. Mamus, SW and Zanjani, ED. (1984) T lymphocytes activated with gamma interferon profoundly inhibit erythropoiesis in vitro. *Blood*, 64:131A.
7. Mamus, SW, Confer D., Kay, NE and Zanjani, ED. (1985) T lymphocyte mediated suppression of erythropoiesis and granulopoiesis in chronic T cell lymphocytosis: Correlation of in vitro and in vivo findings. *Clinical Research* 33:34A.
8. Mamus, SW, Oken, MM and Zanjani, ED. (1985) Suppression of normal human erythropoiesis by recombinant gamma but not alpha-2 interferon is dependent upon monocytes and T cells. *Clinical Research* 33:348A.
9. Mamus, SW, Peterson, LC. And Belzer, M. (1985) Rapid reversal of leukopenia and thrombocytopenia in a homosexual man with Karposi sarcoma by splenectomy. *Clinical Research* 33:348A.
10. Mamus, SW and Zanjani, ED. (1985) Suppression of normal human marrow CFU-GM by human gamma interferon in vitro: Modulation by immunocompetent cells and colony stimulating factor. *Clinical Research* 33:836A.
11. Mamus, SW, Burton, J., Groat, J.D., Lobell, M. and Zanjani, ED. (1985) Mechanism of ibuprofen associated pure white cell aplasia. *Clinical Research* 33:836A.

12. McGlave, P. and Mamus, SW. (1985) Suppression of erythropoiesis in patients with chronic myelogenous leukemia by recombinant alpha-2 interferon. *Clinical Research* 33:836A.
13. Sheikholeslami M, Ma W, Uyeji J, Tornoyos K, Cone L, Mamus S, Keating M, and Albitar M. (2005) Coexistence of Mutated and Unmutated IgVH Forms in Patients with Chronic Lymphocytic Leukemia. *Blood* 106: 4984.
14. Cohn AL, Myers JW, Mamus S, Deur C, Nichol S, Hood K, Khan MM, Ilegbodun D, Kochis J, and Asmar L. (2006) Single-agent pemetrexed in patients with advanced and metastatic hepatoma. *ASCO Gastrointestinal Symposium*, in press.

**RESEARCH**

1989-1990	<b><u>Biotherapeutics</u></b> Co-Principal Investigator ORMC
1990-1991	<b><u>Eastern Cooperative Oncology Group</u></b> Co-Principal Investigator at Orlando Regional Healthcare System
1991-2004	Institutional Investigator for NSABP, GOG and RTOG trials.
2004-present	US Oncology co-investigator in phase I, II and III clinical trials sponsored by the pharmaceutical and biotechnology industries as well as studies sponsored by US Oncology.

**\* Dr. Mamus was the ORHS principle investigator on over 70 clinical trials. In addition, he was co-investigator on over 20 trials with US Oncology.**